Belli Roberta, Bonato Agnese, De Angelis Luciana, Mirabilii Simone, Ricciardi Maria Rosaria, Tafuri Agostino, Molfino Alessio, Gorini Stefania, Leigheb Massimiliano, Costelli Paola, Caruso Maurizia, Muscaritoli Maurizio, Ferraro Elisabetta
Department of Translational and Precision Medicine (Formerly Department of Clinical Medicine), Sapienza University of Rome, Rome, Italy.
Institute of Cell Biology and Neurobiology, National Research Council (CNR), Rome, Italy.
Front Physiol. 2019 Jul 10;10:897. doi: 10.3389/fphys.2019.00897. eCollection 2019.
Sarcopenia is the age-related progressive loss of skeletal muscle mass and strength finally leading to poor physical performance. Impaired myogenesis contributes to the pathogenesis of sarcopenia, while mitochondrial dysfunctions are thought to play a primary role in skeletal muscle loss during aging. Here we studied the link between myogenesis and metabolism. In particular, we analyzed the effect of the metabolic modulator trimetazidine (TMZ) on myogenesis in aging. We show that reprogramming the metabolism by TMZ treatment for 12 consecutive days stimulates myogenic gene expression in skeletal muscle of 22-month-old mice. Our data also reveal that TMZ increases the levels of mitochondrial proteins and stimulates the oxidative metabolism in aged muscles, this finding being in line with our previous observations in cachectic mice. Moreover, we show that, besides TMZ also other types of metabolic modulators (i.e., 5-Aminoimidazole-4-Carboxamide Ribofuranoside-AICAR) can stimulate differentiation of skeletal muscle progenitors . Overall, our results reveal that reprogramming the metabolism stimulates myogenesis while triggering mitochondrial proteins synthesis during aging. Together with the previously reported ability of TMZ to increase muscle strength in aged mice, these new data suggest an interesting non-invasive therapeutic strategy which could contribute to improving muscle quality and neuromuscular communication in the elderly, and counteracting sarcopenia.
肌肉减少症是与年龄相关的骨骼肌质量和力量的逐渐丧失,最终导致身体机能下降。肌生成受损有助于肌肉减少症的发病机制,而线粒体功能障碍被认为在衰老过程中骨骼肌丢失中起主要作用。在这里,我们研究了肌生成与代谢之间的联系。特别是,我们分析了代谢调节剂曲美他嗪(TMZ)对衰老过程中肌生成的影响。我们发现,连续12天用TMZ处理来重新编程代谢,可刺激22月龄小鼠骨骼肌中的肌源性基因表达。我们的数据还显示,TMZ增加了线粒体蛋白水平,并刺激了衰老肌肉中的氧化代谢,这一发现与我们之前在恶病质小鼠中的观察结果一致。此外,我们表明,除了TMZ之外,其他类型的代谢调节剂(即5-氨基咪唑-4-甲酰胺核苷-AICAR)也可以刺激骨骼肌祖细胞的分化。总体而言,我们的结果表明,重新编程代谢在衰老过程中刺激肌生成,同时触发线粒体蛋白合成。连同之前报道的TMZ增加老年小鼠肌肉力量的能力,这些新数据提示了一种有趣的非侵入性治疗策略,这可能有助于改善老年人的肌肉质量和神经肌肉沟通,并对抗肌肉减少症。